Reverse Payment Settlements: How Actavis Activated the Rule of Reason.
- Published in:
- Journal of Corporation Law, 2014, v. 39, n. 4, p. 859
- By:
- Publication type:
- Article
Works matching DE "FEDERAL Trade Commission v. Actavis Inc."
Results: 40
1
2
Update on Antitrust and Pay-for-Delay: Evaluating "No Authorized Generic" and "Exclusive License" Provisions in Hatch-Waxman Settlements.
- Published in:
- San Diego Law Review, 2018, v. 55, n. 1, p. 159
- By:
- Publication type:
- Article
3
PAY-FOR-DELAY SETTLEMENTS IN THE WAKE OF ACTAVIS.
- Published in:
- Michigan Telecommunications & Technology Law Review, 2014, v. 20, n. 2, p. 523
- By:
- Publication type:
- Article
4
PATENT MISUSE AND ANTITRUST: REBIRTH OR FALSE DAWN?
- Published in:
- Michigan Telecommunications & Technology Law Review, 2014, v. 20, n. 2, p. 299
- By:
- Publication type:
- Article
5
A Unified Framework for Competition Policy and Innovation Policy.
- Published in:
- Texas Intellectual Property Law Journal, 2014, v. 22, n. 2, p. 163
- By:
- Publication type:
- Article
6
EARTH TO CONGRESS--THE PHARMACEUTICAL PATENT SYSTEM IS BROKEN--PHARMA PATENTS NEED THEIR OWN SET OF RULES.
- Published in:
- Southern Illinois University Law Journal, 2016, v. 41, n. 1, p. 93
- By:
- Publication type:
- Article
7
A PRESCRIPTION FOR THE FUTURE: REVERSE-PAYMENT SETTLEMENTS IN THE WAKE OF FTC v. ACTAVIS PHARMACEUTICALS.
- Published in:
- Notre Dame Journal of Law, Ethics & Public Policy, 2015, v. 29, n. 2, p. 549
- By:
- Publication type:
- Article
8
Patents at the Supreme Court: It Could've Been Worse.
- Published in:
- Cato Supreme Court Review, 2012, p. 267
- By:
- Publication type:
- Article
9
TAKING A CHILL PILL: WHY SENATE BILL 214 WOULD EFFECTIVELY CHILL PHARMACEUTICAL DEVELOPMENT--AN OVERVIEW OF REVERSE SETTLEMENT "PAY-FOR-DELAY" PRACTICES AND PROPOSED SENATE BILL 214: "PRESERVE ACCESS TO AFFORDABLE GENERICS ACT.".
- Published in:
- University of Cincinnati Law Review, 2014, v. 83, n. 2, p. 577
- By:
- Publication type:
- Article
10
FROM PAY-FOR-DELAY TO PRODUCT FIOPPING: THE LIMITED UTILITY OF ANTITRUST LAW IN THE PHARMACEUTICAL INDUSTRY.
- Published in:
- Cardozo Law Review, 2017, v. 38, n. 5, p. 1915
- By:
- Publication type:
- Article
11
PRESUMPTIVELY ILLEGAL: THE SUPREME COURT'S MISSED OPPORTUNITY IN FTC V. ACTA VIS, INC.
- Published in:
- Capital University Law Review, 2014, v. 42, n. 3, p. 763
- By:
- Publication type:
- Article
12
HATCH-WAXMAN PATENT LITIGATION AND INTER PARTES REVIEW: A NEW SORT OF COMPETITION.
- Published in:
- Alabama Law Review, 2017, v. 69, n. 1, p. 59
- By:
- Publication type:
- Article
13
Patent Challenge Clauses: A New Antitrust Offense?
- Published in:
- Iowa Law Review, 2017, v. 102, n. 4, p. 1477
- By:
- Publication type:
- Article
14
Payment After Actavis.
- Published in:
- Iowa Law Review, 2014, v. 100, n. 1, p. 7
- By:
- Publication type:
- Article
15
REANALYZING REVERSE-PAYMENT SETTLEMENTS: A SOLUTION TO THE PATENTEE'S DILEMMA.
- Published in:
- Cornell Law Review, 2014, v. 99, n. 5, p. 1227
- By:
- Publication type:
- Article
16
Drug Approval in a Learning Health System.
- Published in:
- Minnesota Law Review, 2018, v. 102, n. 6, p. 2413
- By:
- Publication type:
- Article
17
The FTC v. Actavis Roadmap: A Guide to Properly Applying the Rule of Reason Standard in Reverse Payment Cases.
- Published in:
- 2014
- By:
- Publication type:
- Opinion
18
Drug Patent Settlements Around the World.
- Published in:
- Antitrust Bulletin, 2017, v. 62, n. 4, p. 770, doi. 10.1177/0003603X17733357
- By:
- Publication type:
- Article
19
Ending Reverse-Payment Immunity: A Proposed Framework for Antitrust Scrutiny Under California's Cartwright Act.
- Published in:
- McGeorge Law Review, 2014, v. 46, n. 3, p. 659
- By:
- Publication type:
- Article
20
US Court of Appeals applies Actavis to reverse payments settlements without cash transfers.
- Published in:
- Journal of Intellectual Property Law & Practice, 2016, v. 11, n. 10, p. 721, doi. 10.1093/jiplp/jpw118
- By:
- Publication type:
- Article
21
FTC V. ACT AVIS, INC.: ANTITRUST SCRUTINY OF REVERSE PAYMENT SETTLEMENTS IN PHARMACEUTICAL PATENT LITIGATION.
- Published in:
- University of Louisville Law Review, 2014, v. 53, n. 1, p. 115
- By:
- Publication type:
- Article
22
SETTLEMENT SHOULD BE THE END OF STORY: A PROPOSED PROCEDURE TO SETTLE HATCH-WAXMAN PARAGRAPH IV LITIGATIONS MODELED AFTER RULE 23 CLASS ACTION SETTLEMENT PROCEDURE.
- Published in:
- 2016
- By:
- Publication type:
- Opinion
23
Inevitable Imbalance: Why FTC v. Actavis Was Inadequate to Solve the Reverse Payment Settlement Problem and Proposing a New Amendment to the Hatch-Waxman Act.
- Published in:
- Seattle University Law Review, 2014, v. 37, n. 3, p. 1059
- By:
- Publication type:
- Article
24
A Cure for Collusive Settlements: The Case for a Per Se Prohibition on Pay-for-Delay Agreements in Pharmaceutical Patent Litigation.
- Published in:
- Missouri Law Review, 2013, v. 78, n. 3, p. 1353
- By:
- Publication type:
- Article
25
THE FTC HAS A DOG IN THE PATENT MONOPOLY FIGHT: WILL ANTITRUST'S BITE KILL GENERIC CHALLENGES?
- Published in:
- Duke Law & Technology Review, 2015, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article
26
WHY A "LARGE AND UNJUSTIFIED" PAYMENT THRESHOLD IS NOT CONSISTENT WITH ACTAVIS.
- Published in:
- Washington Law Review, 2016, v. 91, n. 1, p. 109
- By:
- Publication type:
- Article
27
BAD MEDICINE: FTC v. ACTAVIS, INC. AND THE MISSED OPPORTUNITY TO RESOLVE THE PAY-FOR-DELAY PROBLEM.
- Published in:
- Maryland Law Review, 2014, v. 73, n. 4, p. 1240
- By:
- Publication type:
- Article
28
A SECOND OPINION ON PHARMACEUTICAL REVERSE PAYMENT SETTLEMENTS: WHY ACTAVIS MISSED THE MARK.
- Published in:
- Georgia State University Law Review, 2014, v. 30, n. 2, p. 561
- By:
- Publication type:
- Article
29
Causation in Reverse Payment Antitrust Claims.
- Published in:
- Stanford Law Review, 2018, v. 70, n. 4, p. 1295
- By:
- Publication type:
- Article
30
Redrawing the Line Between Patent Rights and Antitrust Law: How the U.S. Supreme Court's Over- Extension of Antitrust Law Harms Patent Holders, Damages Innovation, and Discourages Settlements [FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013)].
- Published in:
- Washburn Law Journal, 2014, v. 53, n. 2, p. 365
- By:
- Publication type:
- Article
31
FTC V. ACTAVIS: THE PATENT-ANTITRUST INTERSECTION REVISITED.
- Published in:
- North Carolina Law Review, 2015, v. 93, n. 2, p. 375
- By:
- Publication type:
- Article
32
Understanding Actavis: How Courts Misinterpret FTC v. Actavis, Inc., and How to Get It Right.
- Published in:
- Harvard Negotiation Law Review, 2016, v. 22, p. 111
- By:
- Publication type:
- Article
33
DRUG WARS: A NEW GENERATION OF GENERIC PHARMACEUTICAL DELAY.
- Published in:
- Harvard Journal on Legislation, 2016, v. 53, n. 2, p. 499
- By:
- Publication type:
- Article
34
REVERSE PAYMENT SETTLEMENTS: THE ONGOING DILEMMA AFTER FTC V. ACTAVIS.
- Published in:
- Brooklyn Journal of Corporate, Financial & Commercial Law, 2014, v. 8, n. 2, p. 516
- By:
- Publication type:
- Article
35
A DECADE OF FTC V. ACTAVIS: THE REVERSE PAYMENT FRAMEWORK IS OLDER, BUT ARE COURTS WISER IN APPLYING IT?
- Published in:
- Antitrust Law Journal, 2024, v. 86, n. 2, p. 473
- By:
- Publication type:
- Article
36
THE USE OF MERGER ANALYSIS TECHNIQUES TO ASSESS THE COMPETITIVE EFFECTS OF REVERSE PAYMENT SETTLEMENTS.
- Published in:
- Washington University Law Review, 2014, v. 92, n. 1, p. 193
- By:
- Publication type:
- Article
37
Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 4, p. 316, doi. 10.1038/nbt.2542
- By:
- Publication type:
- Article
38
JUMPING INTO THE ACTAVIS BRIAR PATCH--INSIGHT INTO HOW COURTS MAY STRUCTURE REVERSE PAYMENT ANTITRUST PROCEEDINGS AND THE QUESTIONS THAT ACTAVIS LEFT UNANSWERED.
- Published in:
- William Mitchell Law Review, 2014, v. 40, n. 4, p. 1370
- By:
- Publication type:
- Article
39
ADDITIVE MANUFACTURING, PAY-FOR-DELAY, AND MANDATORY CARE: IS THERE SPACE FOR POSITIVE REFORM?
- Published in:
- Journal of Intellectual Property Law, 2017, v. 24, n. 2, p. 355
- By:
- Publication type:
- Article
40
The Intersection of Patent Infringement and Antitrust Liability in Abbreviated New Drug Application Litigation.
- Published in:
- Journal of Dispute Resolution, 2014, v. 2014, n. 1, p. 51
- By:
- Publication type:
- Article